| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-164-7117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:(S)-3-((2S,3S)-3-Hydroxy-2-methyl-4-methylenenonanoyl)-4-isopropyloxazolidin-2-one
CAS:1239600-18-0
Purity:98+% Package:10mg;25mg;50mg;100mg;250mg Remarks:BD01182956
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
| Products Intro: |
Product Name:LMT-28
CAS:1239600-18-0
Purity:>=98% (HPLC) Package:25MG Remarks:SML1628-25MG
|
LMT-28 manufacturers
- LMT-28
-
- $55.00 / 5mg
-
2025-11-10
- CAS:1239600-18-0
- Min. Order:
- Purity: 99.88%
- Supply Ability: 10g
|
| Product Name: | LMT-28 | | Synonyms: | LMT-28;2-Oxazolidinone, 3-[(2S,3S)-3-hydroxy-2-methyl-4-methylene-1-oxononyl]-4-(1-methylethyl)-, (4S)-;LMT-28 >=98% (HPLC);LMT28,LMT 28;LMT-28, 10 mM in DMSO;(S)-3-((2S,3S)-3-Hydroxy-2-methyl-4-methylenenonanoyl)-4-isopropyloxazolidin-2-one | | CAS: | 1239600-18-0 | | MF: | C17H29NO4 | | MW: | 311.42 | | EINECS: | | | Product Categories: | | | Mol File: | 1239600-18-0.mol |  |
| | LMT-28 Chemical Properties |
| Boiling point | 452.9±38.0 °C(Predicted) | | density | 1.065±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | 100 mg/mL in DMSO (321.11 mM), | | form | oil | | pka | 13.97±0.20(Predicted) | | color | colorless to light yellow, oil | | Water Solubility | < 0.1 mg/mL Water (insoluble) |
| | LMT-28 Usage And Synthesis |
| Uses | LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130[1]. | | Biochem/physiol Actions | LMT-28 is a derivative of oxazolidinone. It has the ability to repress the activation of signal transducer and activator of transcription 3 (STAT3) stimulated by interleukin 6 (IL-6). Orally administered LMT-28 reduced arthritis and acute pancreatitis stimulated by collagen in mice pathologic models. | | in vivo | LMT-28 (0-0.5 mg/kg; p.o.; once daily for 15 days) alleviates CIA in mice[1].
LMT-28 (0.25 or 1 mg/kg; p.o.) ameliorates the progression of pancreatitis in mice. LMT-28 binds directly and specifically to gp130, and thereby inhibits the interaction of gp130 with the IL-6/IL-6Rα complex[1]. | Animal Model: | Six-week-old male DBA/1J mice (collagen-induced arthritis mice, CIA)[1] | | Dosage: | 0-0.5 mg/kg | | Administration: | Oral; once daily for 15 days | | Result: | Markedly reduced the serum levels of cartilage oligomeric matrix protein (COMP) by 50%, serum amyloid P (SAP) by 55%, and anti-CII IgG by 62%.
|
| | IC 50 | IL-6 | | References | [1] Hong SS, et al. A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130. J Immunol. 2015 Jul 1;195(1):237-45. DOI:10.4049/jimmunol.1402908 |
| | LMT-28 Preparation Products And Raw materials |
|